Latest Breaking News On - Antony mattessich - Page 5 : vimarsana.com

Ocular Therapeutix™ Announces 12-Month Topline Data from

OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period OTX-TKI.

United statesPark cityRabia gurses ozdenChris brinzeyAntony mattessichBen shannonArshadm khananiPeterk kaiserDonald notmanOcular therapeutix incRetinal pharmaceuticals marketClinical research at sierra eye associatesExchange commissionClinical researchSierra eye associatesClinical trials

Ocular Therapeutix Announces 12-Month Topline Data from Ongoing U S -Based Phase 1 Clinical Trial Evaluating OTX-TKI for Treatment of Wet AMD

11.06.2023 - OTX-TKI maintained vision and CSFT comparable to aflibercept every eight weeks, with 89% reduction in treatment burden over a 12-month period OTX-TKI demonstrated no drug-related ocular or systemic serious adverse events in the trial through Month . Seite 1

United statesPark cityArshadm khananiAntony mattessichClinical research at sierra eye associatesOcular therapeutix incClinical researchSierra eye associatesClinical trialsChief executive officer

Ocular Therapeutix™ To Present 12-Month Top-Line Data from U S -Based Phase 1 Clinical Trial of OTX-TKI in Wet Age-Related Macular Degeneration at the 2023 Clinical Trials at the Summit Annual Meeting

BEDFORD, Mass., June 05, 2023 Ocular Therapeutix, Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and. | June 5, 2023

Park cityUnited statesArshadm khananiJeffrey heierPeterk kaiserReenie mccarthyAlexander hardyChris brinzeyJoel naorMohamed geneadRabia gurses ozdenDonald notmanAntony mattessichVictor perlrothExchange commissionGlobenewswire inc

Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference

Ocular Therapeutix™ to Present at the Jefferies Global Healthcare Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesInvestorsocular therapeutixdonald notmanchiefWestwicke chris brinzeymanagingAntony mattessichOcular therapeutix incMarriott marquisWall streetChief executive officerOcular therapeutixJefferies global healthcare conferenceChris brinzeymanaging

Ocular Therapeutix Provides First Quarter 2023 Financial Results and Corporate Update

08.05.2023 - 12-month Top-Line Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD to be Presented in June at the Clinical Trials at the Summit 2023 Meeting Presented Pre-Clinical and Clinical .

Park cityUnited statesDonald notmanChris brinzeyAntony mattessichAssociation for researchAssurance programOcular therapeutix incExchange commissionProduct revenueFirst quarterRepresenting growthYear endingRepresenting anticipated growthClinic trialsClinical data